ELI LILLY & Co is 82.9x more valuable than Axsome Therapeutics, Inc. by market capitalization ($1.070 T vs $12.91 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AXSM | LLY |
|---|---|---|
| Market cap | $12.91 B | $1.070 T |
| US-listed rank | #801 | #10 |
| Revenue (latest FY) | $638.50M | $65.18B |
| Net income (latest FY) | -$183.17M | $20.64B |
| Net margin | -28.7% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 634 | 989 |
ELI LILLY & Co is 82.9x more valuable than Axsome Therapeutics, Inc. by market capitalization ($1.070 T vs $12.91 B).
In their latest fiscal years, Axsome Therapeutics, Inc. reported $638.50M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Axsome Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.